Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism

• Published in: Contraception (Stoneham) Vol. 71; no. 6; pp. 409 - 416
• Main Authors: Klipping, Christine, Marr, Joachim
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.06.2005; Elsevier Science
• Subjects: Biological and medical sciences; Birth control; Carbohydrate metabolism; Drospirenone; Genital system. Reproduction; Gynecology. Andrology. Obstetrics; Hormonal contraception; Lipid metabolism; Medical sciences; Oral contraceptives; Pharmacology. Drug treatments; Carbohydrate metabolism; Lipid metabolism; Oral contraceptives; Drospirenone; Ethinylestradiol; Human; Desogestrel; Estrogen; Oral administration; Lipids; Metabolism; Estrane derivatives; Progestagen; Hemostasis; Female; Contraceptive; Carbohydrate; Comparative study
• ISSN: 0010-7824; 1879-0518
• DOI: 10.1016/j.contraception.2004.12.005

To compare the effect of ethinyl estradiol 20 μg/drospirenone 3 mg (EE 20 μg/DRSP 3 mg) administered according to a 24/4 regimen with ethinyl estradiol 20 μg/desogestrel 150 μg (EE 20 μg/DSG 150 μg) administered according to the conventional 21/7 regimen on lipid, carbohydrate and hemostatic parameters. In this open-label study, healthy women were randomized to EE 20 μg/DRSP 3 mg or EE 20 μg/DSG 150 μg for seven cycles. Mean differences in high-density lipoprotein (HDL)- and low-density lipoprotein (LDL)-cholesterol levels at cycle 7 compared to baseline were assessed. Secondary variables included changes in other lipid, hemostatic and carbohydrate parameters. Both treatments increased HDL-cholesterol, but decreased LDL-cholesterol by a comparable extent. Although slightly elevated in both groups, blood glucose and C-peptide levels measured during oral glucose tolerance tests were within normal reference ranges at cycle 7. Overall, the differences in lipid, hemostatic or carbohydrate parameters were not significant between the two treatments. EE 20 μg/DRSP 3 mg has a good safety profile comparable with EE 20 μg/DSG 150 μg.